Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19866351 | 0.88 | — | — | |
| Piperazine SCHEMBL28203228 | 0.87 | HIF1A (0.30) | — | |
| Pyrrole SCHEMBL28017044 | 0.86 | ALDH1A1 (0.30) | ALDH1A1FKBP5 | |
| Pyrrole SCHEMBL28796585 | 0.86 | ALDH1A1 (0.30) | ALDH1A1FKBP5 | |
| Pyrimidine SCHEMBL1880807 | 0.84 | FDPS (0.35) | — | |
| Pyrimidine SCHEMBL27833173 | 0.84 | — | — | |
| SCHEMBL13616372 | 0.83 | — | — | |
| SCHEMBL15243317 | 0.80 | — | — | |
| SCHEMBL30200271 | 0.80 | TSHR (0.60) | ALDH1A1FKBP5TSHRNAPRTTDP1 | |
| Pyridine SCHEMBL20598704 | 0.80 | TSHR (0.60) | ALDH1A1FKBP5TSHRNAPRTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 248 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118005948-B | Electrolyte additive and preparation method and application thereof | 蓝固(湖州)新能源科技有限公司 | 2024-06-28 | — | — | CN | claimed |
| CN-118236513-A | Paclitaxel immunoregulation hydrogel preparation and preparation method and application thereof | 上海交通大学 | 2024-06-25 | — | — | CN | claimed |
| CN-118005948-A | Electrolyte additive and preparation method and application thereof | 蓝固(湖州)新能源科技有限公司 | 2024-05-10 | — | — | CN | claimed |
| CN-113831491-B | Preparation method and adsorption application of pyrimidazole covalent organic framework | 南昌大学 | 2023-03-24 | — | — | CN | claimed |
| CN-113831491-A | Preparation method and adsorption application of pyrimidazole covalent organic framework | 南昌大学 | 2021-12-24 | — | — | CN | claimed |
| CN-109912661-A | Pyrimidine with catalytic performance-pyrazoles ruthenium complex and preparation method thereof | 厦门大学 | 2019-06-21 | — | — | CN | claimed |
| EP-2042504-B1 | Fused azole-pyrimidine derivatives | BAYER SCHERING PHARMA AG (DE) | 2011-06-01 | — | — | EP | claimed |
| US-20090270388-A1 | FUSED AZOLE-PYRIMIDINE DERIVATIVES | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-10-29 | — | — | US | claimed |
| EP-2042504-A1 | Fused azole-pyrimidine derivatives | Bayer HealthCare AG (DE) | 2009-04-01 | — | — | EP | claimed |
| US-7511041-B2 | Fused azole-pyrimidine derivatives | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-03-31 | — | — | US | claimed |
| EP-1549652-B1 | FUSED AZOLE-PYRIMIDINE DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2008-10-22 | — | — | EP | claimed |
| CN-100384846-C | Fused azole-pyrimidine derivatives | BAYER PHARMACEUTICALS CORP (US) | 2008-04-30 | — | — | CN | claimed |
| US-20060128732-A1 | Fused azole-pyrimidine derivatives | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-06-15 | — | — | US | claimed |
| CN-1688582-A | Fused azole-pyrimidine derivatives | BAYER PHARMACEUTICALS CORP (US) | 2005-10-26 | — | — | CN | claimed |
| EP-1549652-A1 | FUSED AZOLE-PYRIMIDINE DERIVATIVES | Bayer Pharmaceuticals Corporation (US) | 2005-07-06 | — | — | EP | claimed |
| WO-2004111052-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS MODULATORS OF MULTI-DRUG RESISTANCE (MDR) | XENOVA LIMITED (GB) | 2004-12-23 | — | — | WO | claimed |
| WO-2004029055-A1 | FUSED AZOLE-PYRIMIDINE DERIVATIVES | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-04-08 | — | — | WO | claimed |
| CN-112969790-B | Compositions and methods for delivering nucleobase editing systems | 比姆医疗股份有限公司 | 2024-07-05 | — | — | CN | disclosed |
| US-20020028782-A1 | Pyrrolo [2, 3d] pyrimidine compositions and their use | OSI PHARMACEUTICALS, INC. | 2002-03-07 | — | — | US | disclosed |
| WO-2001039777-A1 | COMPOUNDS SPECIFIC TO ADENOSINE A1 A2A, AND A3 RECEPTORS AND USES THEREOF | OSI PHARMACEUTICALS, INC. (US) | 2001-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270388-A1 | FUSED AZOLE-PYRIMIDINE DERIVATIVES | PIK3CA, PIK3CD, PIK3R5 | ALDH1A1 4300/4885FKBP5 167/4885TSHR 582/4885 |
| US-20060128732-A1 | Fused azole-pyrimidine derivatives | PIK3CA, PIK3CD, PIK3CG | ALDH1A1 4097/4885FKBP5 147/4885TSHR 488/4885 |
| US-20020028782-A1 | Pyrrolo [2, 3d] pyrimidine compositions and their use | TYMP, UMPS, ADORA3 | ALDH1A1 1901/4885FKBP5 2002/4885TSHR 1424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.